Maurice Perol, MD, discusses the persistent unmet need for effective treatments following progression on immunotherapy in NSCLC.
Maurice Perol, MD, Léon Bérard Cancer Center
Advertisement
Articles by Maurice Perol, MD, Léon Bérard Cancer Center
Advertisement
Latest Updated Articles
Dr Perol on Unmet Need for Post Immunotherapy Strategies in Lung CancerPublished: October 16th 2025 | Updated:
Standard of Care for EGFR+ ES-NSCLCPublished: October 20th 2020 | Updated:
Practical Implications of ADAURA in NSCLCPublished: October 20th 2020 | Updated:
Molecular Testing in Early-Stage NSCLCPublished: October 20th 2020 | Updated:
Testing for EGFR in NSCLC WorldwidePublished: October 20th 2020 | Updated:
Adjuvant Approaches in EGFR+ NSCLCPublished: October 20th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5